Literature DB >> 1832905

Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers.

G Granata1, D Coradini, V Cappelletti, G Di Fronzo.   

Abstract

The concentration of total cathepsin D in cytosols of 199 node negative women with primary breast cancer in a 10-year retrospective cohort was assayed. Cathepsin D status alone was unable to predict disease-free or overall survival. However, those patients with receptor positive tumours who were cathepsin D positive had shorter [corrected] disease-free (P = 0.02) and overall survival (P = 0.01) than cathepsin D negative patients. Therefore, measurement of cathepsin D appears to provide additional prognostic information for the prediction of disease-free and overall survival in patients with node negative breast cancer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832905     DOI: 10.1016/0277-5379(91)90260-k

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods.

Authors:  U J Göhring; A Scharl; U Thelen; A Ahr; G Crombach; B R Titius
Journal:  J Clin Pathol       Date:  1996-01       Impact factor: 3.411

2.  Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables.

Authors:  S Veneroni; M G Daidone; G Di Fronzo; V Cappelletti; D Amadori; A Riccobon; A Paradiso; M Correale; R Silvestrini
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

3.  Comparative biochemical and immunohistochemical studies on the cathepsin D content of human breast cancer.

Authors:  W Remmele; J Sauer-Manthey
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

Review 4.  Evaluation of cathepsin D as a prognostic factor in breast cancer.

Authors:  P M Ravdin
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells.

Authors:  A E O'Donoghue; D N Poller; J A Bell; M H Galea; C W Elston; R W Blamey; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

6.  Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.

Authors:  T Jahkola; T Toivonen; K von Smitten; I Virtanen; V M Wasenius; C Blomqvist
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

7.  Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.

Authors:  P Pujol; J P Daurès; J P Brouillet; T Maudelonde; H Rochefort; J Grenier
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

8.  Prognostic role of high cathepsin D expression in breast cancer: a systematic review and meta-analysis.

Authors:  Junho Kang; Yeuni Yu; Seongdo Jeong; Hansong Lee; Hye Jin Heo; Jeong Jun Park; Hee Sam Na; Dai Sik Ko; Yun Hak Kim
Journal:  Ther Adv Med Oncol       Date:  2020-06-08       Impact factor: 8.168

9.  Prognostic value of Ki-67 immunolabelling in primary operable breast cancer.

Authors:  M Railo; S Nordling; K von Boguslawsky; M Leivonen; L Kyllönen; K von Smitten
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

10.  Stromal cell cathepsin D expression and long-term survival in breast cancer.

Authors:  H Joensuu; S Toikkanen; J Isola
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.